Anavex Life Sciences Files Q1 2025 10-Q

TL;DR

ANAVEX 10-Q filed: Q1 2025 financials out, check balance sheet details.

AI Summary

Anavex Life Sciences Corp. filed its 10-Q for the period ending December 31, 2024. The company, focused on biological products, reported financial data for the first quarter of fiscal year 2025. Key financial statement items like common stock, additional paid-in capital, and retained earnings were detailed for the periods ending December 31, 2024, and September 30, 2024, as well as comparative periods in 2023.

Why It Matters

This filing provides investors with a quarterly update on Anavex's financial health and performance, crucial for understanding the company's operational status and potential.

Risk Assessment

Risk Level: medium — Biotech companies often carry higher risk due to the nature of drug development and regulatory hurdles.

Key Numbers

• 2024-12-31 — Reporting Period End Date (Indicates the end of the fiscal quarter for which financial information is reported.)
• 2025-02-12 — Filing Date (Shows when the 10-Q was officially submitted to the SEC.)
• 0930 — Fiscal Year End (Specifies the end date of Anavex's fiscal year.)

Key Players & Entities

• ANAVEX LIFE SCIENCES CORP. (company) — Filer of the 10-Q
• 20241231 (date) — End of reporting period
• 20250212 (date) — Filing date
• 0001314052 (company) — Central Index Key for Anavex Life Sciences Corp.

FAQ

Key Financial Figures

• $0.001 — ich Registered Common Stock Par Value $0.001 AVXL NASDAQ Stock Market LLC Indi
• $150.0 million — ary 3, 2023, the Company entered into a $150.0 million purchase agreement (the "2023 Purchase

Filing Documents

• e6338_10-q.htm (10-Q) — 518KB
• e6338_ex31-1.htm (EX-31.1) — 8KB
• e6338_ex31-2.htm (EX-31.2) — 8KB
• e6338_ex32-1.htm (EX-32.1) — 6KB
• image_001.jpg (GRAPHIC) — 28KB
• image_002.jpg (GRAPHIC) — 28KB
• 0001731122-25-000205.txt ( ) — 2740KB
• avxl-20241231.xsd (EX-101.SCH) — 23KB
• avxl-20241231_cal.xml (EX-101.CAL) — 24KB
• avxl-20241231_def.xml (EX-101.DEF) — 69KB
• avxl-20241231_lab.xml (EX-101.LAB) — 184KB
• avxl-20241231_pre.xml (EX-101.PRE) — 139KB
• e6338_10-q_htm.xml (XML) — 318KB

– FINANCIAL INFORMATION

PART I – FINANCIAL INFORMATION 4

FINANCIAL STATEMENTS

ITEM 1. FINANCIAL STATEMENTS 4

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS. 18

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISKS

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISKS. 37

CONTROLS AND PROCEDURES

ITEM 4. CONTROLS AND PROCEDURES 37

– OTHER INFORMATION

PART II – OTHER INFORMATION 38

LEGAL PROCEEDINGS

ITEM 1. LEGAL PROCEEDINGS 38

RISK FACTORS

ITEM 1A. RISK FACTORS 39

UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS 39

DEFAULTS UPON SENIOR SECURITIES

ITEM 3. DEFAULTS UPON SENIOR SECURITIES 39

MINE SAFETY DISCLOSURES

ITEM 4. MINE SAFETY DISCLOSURES 39

OTHER INFORMATION

ITEM 5. OTHER INFORMATION 39

EXHIBITS

ITEM 6. EXHIBITS 40

– FINANCIAL INFORMATION

PART I – FINANCIAL INFORMATION

FINANCIAL STATEMENTS

ITEM 1. FINANCIAL STATEMENTS ANAVEX LIFE SCIENCES CORP. CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS December 31, 2024 (Unaudited) 4 Anavex Life Sciences Corp. Condensed Consolidated Interim Balance Sheets (in thousands, except share and per share amounts) December 31, September 30, 2024 2024 (Unaudited) Assets Current Cash and cash equivalents $ 120,775 $ 132,187 Incentive and tax receivables 2,557 2,449 Prepaid expenses and other current assets 711 931 Total Assets $ 124,043 $ 135,567 Liabilities and Stockholders' Equity Current Liabilities Accounts payable $ 4,567 $ 9,627 Accrued liabilities - Note 3 7,732 4,835 Deferred grant income - Note 4 829 842 Total Liabilities $ 13,128 $ 15,304 Commitments and Contingencies - Note 6 — — Capital stock Authorized: 10,000,000 preferred stock, par value $ 0.001 per share — — 200,000,000 common stock, par value $ 0.001 per share Issued and outstanding: 84,985,449 common shares (September 30, 2024 - 84,795,517 ) 85 85 Additional paid-in capital 459,012 456,249 Accumulated deficit ( 348,182 ) ( 336,071 ) Total Stockholders' Equity $ 110,915 $ 120,263 Total Liabilities and Stockholders' Equity $ 124,043 $ 135,567 See Accompanying Notes to Condensed Consolidated Interim Financial Statements 5 Anavex Life Sciences Corp. Condensed Consolidated Interim Statements of Operations and Comprehensive Loss (in thousands, except share and per share amounts) (Unaudited) Three months ended December 31, 2024 2023 Operating expenses General and administrative $ 3,146 $ 2,694 Research and development 10,446 8,684 Total operating expenses 13,592 11,378 Operating loss ( 13,592 ) ( 11,378 ) Other income (expense) Grant income 12 — Research and development incentive income 412 592 Interest income, net 1,394 2,008 Foreign exchange gain (loss) ( 337 ) 156 Total other income, net 1,481 2,756 Net

Business

Business Anavex Life Sciences Corp. ("Anavex" or the "Company") is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system ("CNS") diseases with high unmet need. Anavex analyzes genomic data from clinical trials to identify biomarkers, which are used in the analysis of its clinical trials for the treatment of neurodegenerative and neurodevelopmental diseases. The Company's focus is on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Note 2 Basis of Presentation These accompanying unaudited condensed consolidated interim financial statements have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission ("SEC") and accounting principles generally accepted in the United States of America ("U.S. GAAP") for interim reporting. Accordingly, certain information and note disclosures normally included in the annual financial statements in accordance with U.S. GAAP have been condensed or omitted pursuant to such rules and regulations. In the opinion of management, the disclosures are adequate to make the information presented not misleading. These accompanying unaudited condensed consolidated interim financial statements reflect all adjustments, consisting of normal recurring adjustments, which in the opinion of management are necessary for fair presentation of the information contained herein. The consolidated balance sheet as of September 30, 2024 was derived from the audited annual financial statements but does not include all disclosures required by U.S. GAAP. The accompanying unaudited condensed consolidated interim financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Comp

View Full Filing

View this 10-Q filing on SEC EDGAR